What is the half‑life of Ryzodeg (insulin degludec/insulin aspart)?

Half-Life of Ryzodeg (Insulin Degludec/Insulin Aspart)

The half-life of the insulin degludec component in Ryzodeg is approximately 25 hours, which is roughly twice as long as insulin glargine's 12-hour half-life. 1, 2, 3

Pharmacokinetic Profile of Insulin Degludec

• Insulin degludec, the basal component of Ryzodeg, has a terminal half-life exceeding 25 hours in both type 1 and type 2 diabetes patients at steady state. 1, 2, 3
• This ultra-long half-life is approximately twice that of insulin glargine (which has a half-life of approximately 12 hours). 2, 3
• The duration of action of insulin degludec extends beyond 42 hours in euglycemic clamp studies, far exceeding the 24-hour coverage of conventional basal insulins. 1, 2, 4

Steady-State Characteristics

• Insulin degludec reaches steady state after approximately 3 days of once-daily dosing. 2, 3
• Despite its long half-life, once-daily degludec does not cause accumulation of insulin in the circulation after reaching steady state. 5
• At steady state, the pharmacokinetic profile demonstrates an even distribution of exposure across one dosing interval, with a near-constant effect that varies little from injection to injection. 1, 3

Mechanism of Protracted Absorption

• The ultra-long half-life results from insulin degludec's unique mechanism of forming a depot of soluble multihexamer chains after subcutaneous injection. 1, 5, 3
• These multihexamer chains subsequently release degludec monomers that are absorbed at a slow and steady rate into the circulation. 5
• This mechanism produces a flat, peakless pharmacodynamic profile with four times lower day-to-day within-subject variability in glucose-lowering effect compared to insulin glargine. 2, 3

Clinical Implications of the Extended Half-Life

• The 25-hour half-life and >42-hour duration of action allow for flexible dosing intervals without compromising efficacy or safety. 1, 5, 4
• Studies testing extreme dosing intervals of 8 and 40 hours showed no detriment in glycemic control or hypoglycemic frequency versus insulin glargine given at the same time each day. 5
• The extended half-life contributes to a lower risk of nocturnal hypoglycemia compared to insulin glargine—approximately 25% reduction in type 1 diabetes and 26% reduction in pooled populations. 6, 4

Comparison with Other Basal Insulins

• Insulin degludec's half-life of >25 hours is substantially longer than insulin glargine's ~12 hours. 2, 3
• The American Diabetes Association classifies degludec among "new longer-acting basal analogs" that may confer lower hypoglycemia risk compared to U-100 glargine in patients with type 1 diabetes. 6, 7
• The ultra-long half-life and flat profile represent a significant pharmacokinetic advantage over earlier basal insulin formulations. 1, 3

Important Clinical Caveats

• While the degludec component has a 25-hour half-life, the insulin aspart component in Ryzodeg has a much shorter duration of action (3-5 hours), typical of rapid-acting insulin analogs. 7
• The extended half-life means that dose adjustments may take longer to reach full effect—approximately 3 days to reach steady state. 2, 3
• For patients switching from other basal insulins to degludec-containing products, close monitoring during the first week is essential as steady-state levels are established. 3